Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 8.6% in November

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Based on an average daily trading volume, of 321,400 shares, the days-to-cover ratio is currently 9.8 days. Currently, 6.5% of the company’s shares are sold short.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $9.52 on Monday. Astria Therapeutics has a 1-year low of $5.80 and a 1-year high of $16.90. The business has a fifty day moving average price of $10.82 and a 200 day moving average price of $10.70. The stock has a market capitalization of $537.21 million, a P/E ratio of -4.56 and a beta of 0.67.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Oppenheimer raised their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Astria Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $25.60.

Hedge Funds Weigh In On Astria Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Quest Partners LLC boosted its holdings in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,112 shares in the last quarter. PDT Partners LLC bought a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new stake in Astria Therapeutics during the third quarter valued at approximately $155,000. Hsbc Holdings PLC acquired a new stake in Astria Therapeutics in the second quarter valued at approximately $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the first quarter worth $200,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.